Neucruit has been helping rapid lateral flow testing for COVID-19

Neucruit has been helping rapid lateral flow testing for COVID-19

Costumer

This client is an innovative health company making medicine more proactive

Challenge

Finding sufficient patients that were in the specific 2-5 day window of COVID infection

Solution

Neucruit provided the patient recruitment solution, utilising social media to outreach to potential patients

Results

Neucruit recruited all 30 patients with viral COVID-19 (in days 2-5 of symptoms) in 28 days, reducing timelines by 93%

About the client

Our client is a predictive health company focused on making medicine more proactive. They are an innovative UK, and VC backed start-up supported by one of the UK’s top universities.

‘A team of scientists, engineers, and designers solving the world’s most critical healthcare problems.’

" Neucruit facilitated a 93% reduction in outreach timelines"

Using Neucruit to accelerate research 

The clients’ team approached Neucruit after struggling to recruit sufficient participants to test their novel lateral flow test.

Finding these patients and efficiently processing them within their infective period was difficult, also the study organisers had recruited only 5 patients in 48 days. This significantly delayed the validation of their lateral flow tests.

Nevertheless, Neucruit successfully recruited all 30 patients with viral COVID-19 (in days 2-5 of symptoms) within 28 days, reducing timelines by 93%.

About Neucruit

Neucruit is a global platform that uses real-time data to help biopharmaceutical companies, site teams, and investigators enhance clinical research planning and delivery through intelligent analytics on the patient journey. Furthermore, Neucruit combines unique patient insights with longitudinal clinical data to optimise site selection patient recruitment and gain insights that can’t be easily accessed through traditional methods. If you want to know more about us and our work, please contact us.

Recommended Posts